Absence epilepsy in Malta by Mifsud, Marisa
ABSENCE EPILEPSY IN MAL TA 
Marisa Mifsud 
Introduction 
Absence epilepsy (AE), more commonly known as petit mal, is 
characterised by absences with bilaterally symmetrical and synchronous 
24Hz spike-and-slow waves on the EEG. It is a relatively uncommon 
type of epilepsy, occurring most often in children, and accounting for 5% -
10% of all childhood seizures. 
The typical absence consists of a momentary disturbance of consciousness 
during which the patient stares blankly for a few seconds. Other 
symptoms, namely mild clonic components, atomic and tonic components, 
antoniatimis and autonomic phenomena, may also be associated with 
absences. 
Absence epilepsy is often described as benign and rarely continues into 
adult life. However a high incidence of generalised tonic clonic seizures 
(GTCS) has been reported in absence patients, leading t<;> persistance of 
seizures after adolescence. Modern treatment of AE includes 
ethosuximide and the more recent drug, sodium valproate. 
Methodology 
Study I 
The incidence of Absence Epilepsy in Malta 
Records of the EEGs performed at the Neurophysiology Department at 
St. Luke's Hospital in the years 1985 - 1991 were reviewed, and patients 
who ha<:i recordings of bilaterally symmetrical and syncJlronous 2-4Hz 
spike and discharges (2Hz SP-W), were included in the study. 
Only records of the request forms of EEGs performed in 1990 and 1991 were 
'kept at the Neurophysiology Department. These were reviewed for cases 
where the presenting complaints were absences, and where the EEG 
failed to show any changes. The medical histories of these patients were 
checked for AE. 
The Schedule V forms of patients with chronic illnesses applying for the 
supply of free drugs in 1991, kept at the Almoner's Section at St. Luke's 
Hospital, were reviewed for patients on treatment with ethosuximide or 
sodium valproate. The medical histories of these patients were sent for 
and checked for absence epilepsy. 
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Study 11 
Clinical aspects of Absence Epilepsy in Malta 
The medical histories of the patients found in Study I, were reviewed. 
Data on age, age at onset of AE, family history, seizure control and 
treatment was collected. 
Study III 
Patient Interviews 
The main aims of the interviews with patients with absence epilepsy 
were: 
a) to assess patient compliance 
b) to identify the side-effects experienced by the patients 
c) to assess the patient-pharmacist relationship 
An appointment for an interview at the Neurology Out Patient's Clinic at 
St. Luke's Hospital was sent by post to all mentally normal absence 
patients; these were mostly adults who regularly attend this clinic. 
Children with AE were simply interviewed when they attended for a 
regular appointment at the Children's Out Patient Clinic. 
Study IV 
Uri~alysis of samples from Patients taking ethosuximide 
A urine sample was collected from each of the six patients interviewed in 
Study III who were on treatment with ethosuximide. 
The metabolites and unchanged drug were extracted from the urine with 
chloroform and four different fractions were separated using thin layer 
chromatography. The four different bands were given a number from I to 
IV, I being given to the most polar fraction remaining closest to the 
original point of application of the sample, and IV being the fraction 
which migrated furthest from the origin. The Rf values of the four 
different fractions were calculated (Table 1). 
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The four different bands on the chromatogram were scraped off 
separately so as to isolate the four extracted fractions. 
The different fractions were extracted from the silica into the 
chloroform, and an IR spectrum was obtained for each fraction. 
The IR spectra showed the presence of the succinimide ring characteristic 
of ethosuximide and its metabolites in these four fractions, and also in 
the polar residue left at the original point of application of the sample. 
Table 1: Rf values of urine extracts 
Extracts Rf values obtained from TLC of the different 
I 
II 
III 
IV 
Results: 
sample extracts 
Range 
0.035 - 0.063 
0.082 - 0.142 
0.481 - 0.590 
0.887 - 0.944 
Study 1: Incidence of Absence Epilepsy in Malta 
Average 
0.046 
0.113 
0.541 
0.920 
In the period 1985 - 1991, 34 patients were diagnosed to have EEG 
recordings of 3Hz SP-W discharges for the first time. 7 of these patients 
had seizures other than absences. Therefore, in the seven ,year period, 27 
patients were diagnosed to have AE, giving an average of 39 new cases of 
AE annually. 
There was a mean annual incidence of 1.1 cases per 100,000 people. Since 
26 out of 27 patients were children under 16 years of age, there was a mean 
annual incidence of 4.2 cases per 100,000 children aged 0 - 15 years of age 
(Table 2). 
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TLC Chromatogram of Urine extracts 
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Table 2: Comparison of Incidence of AE in Malta with that in other 
countries 
Age group 
children 
0-15 years 
all ages 
Study II 
Incidence of AE/100,OOO population 
Malta Sweden 
4.2 7.0 
Denmark 
1.1 0.8 
66.7% (n=18) of the patients with AE were found to suffer only from 
absences, 22.2% (n=6) have GTCS in addition to absences and 11.1 % (n=3) 
were patients with diffuse brain damage some of which have other 
seizure types in addition to absences. 
A history of seizures among close relatives (parents, siblings, 
grandparents anq parents' siblings) was found in 39.1 % of the patients 
and slightly more frequent in "children with initial absences followed by 
GTCS. This is high compared to the family history of seizures found in 
children with AE in Sweden (Table 3). Febrile convultions had preceeded 
in children with initial GTCS. 
In 24 patients found to suffer from absences only valproate was used as the 
drug of first choice in 83.3% (n=20). It was efficient in 80% of these cases 
(n=16). However, 10% (n=2) of the patients beCame seizure-free with 
ethosuximide monotherapy, 5% (1\=1) required a combination of both 
drugs for control and the remaining case (5% preferred single absences to 
anti-epileptic drug therapy. Ethosuximide as the initial therapy for AE 
was used in 16.7% of the cases (n=4). It was efficient in 50% of the 
patients (n=2), with the other patients (n=2) requiring poly therapy for 
seizure control (Table 4). 
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Table 3: Family history and history of febrile seizures in AE patients in 
Malta and Sweden 
Clinical Subgroups 
Family Absences Initial Initial Total 
History only absences GTCS % (n) 
+GTCS % (n) % (n) 
% (n) 
Maltese 
Study (1992) 35.3(6) 66.7 (2) 33.3 (1) 39.1 (9) 
Swedish 
Study (1988) 14 29 10 19 
Febrile 
Seizures 
% (n) 
Maltese 
Study (1992) 11.8 (2) 33.3 (1) 33.3 (1) 17.4 (4) 
Swedish 
Study (1988) 11 13 50 15 
Table 4: Treatment and response in 24 patients suffering from absences = /-
GTCS 
Drug(s) 
VPA 
ESM 
VPA+ESM 
VPA+ ESM 
+CZP 
No. of patients 
on initial 
therapy 
n % 
20 
4 
83.3 
16.7 
Response to Final 
initial 
therapy 
Good Poor Nil 
16 
2 
a: 2 patients controlled with ESM 
1 controlled with VP A + ESM combination 
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treatment and 
response 
Good Poor 
16 
4 
2 
1 
1 prefered absences to drug therapy 
b: controlled-en ESM + VP A combination 
c: controlled on ESM + VP A + CZP combination 
Table 5: Seizure control in patients suffering from absences only and those 
with GTCS in addition to absences 
Seizure type 
absences only 
n=18 
absences + GTCS 
n=6 
No. of patients controlled with Treatment 
1 year after start 2 years after start 
n % n % 
15 83.3 17 94.4 
1 16,6 3 50.0 
Study m: (i) Patient Compliance 
(The interview was carried out with 72% (n=18) of the 25 patients who 
qualified for the interview). 
Only 16.7% (n=3) of the patients interviewed were found to be non 
compliant. The frequency of missed doses tended to be higher in adult 
patients, in those who have been epileptic for 10 years or longer, in 
patients on poly therapy and in those taking frequent daily doses. 
(ii) Side Effects in Absence Patients 
66.7% (n=12) of the patients interviewed experienced some kind of 
adverse effect due to their medication. 77.8% (n=7) of the patients on 
poly therapy as compared to 55% (n=5) of those on monotherapy, have 
suffered from side effects. 
Only 11.1% of the patients interviewed (n=2) had been informed of the 
side-effects of th~ir medication by the pharmacist, whereas 46.2% of the 
patients (n=9) became aware of these side-effects through reading 
product literature. 
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(Hi) The Patient-Pharmacist relationship 
Only 27.8% (n=5) of the patients interviewed had informed the 
cQmmunity pharmacist in their home tQwn or village, about their 
condition, and only 16.7% (n=3) asked the dispensary pharmacist advise 
about their medication. Older patients, patients who have been 
epileptics for 10 ye~rs and longer and patients who had GTCS in addition 
to absences were less likely to consult the pharmacist for advice or 
information. 
Discussion 
Althougl1 absence epilepsy is often described in textbooks as benign and 
seldom continues beyond adult life, this is a rather optimistic outlook 
regarding the prognoses of AE. 
An unfavourable outcome of AE is associated with the appearance of 
GTCS. In this study 6 patients were found to have been suffering from AE 
for 20 - 40 years (median 33 years). These patients have- GTCS in 
addition to absences, and the onset of GTCS was in the range between 5 -
21 years (median 16 years) after onset of absences. 
Recurrences of seizures uSJlally occur within the first 2 years of treatment, 
but recurrences of up to 20 years after termination of treatment have been 
reported. 
Therefore, good social adaption is important in the epileptic. This is 
effected by the patient's own, attitude to epilepsy, its severity and its 
impact on their lives. Most absence epilepsy patients wanted to know 
more about their condition, and its treatment, mostly through leaflets but 
even through attending special lectures, and watching special TV 
programs or videos. 22.2% (n=4) of. the patients interviewed, 
spontaneously suggested that a Maltese Epilepsy Society should be set 
up. 
Yet, only 27.7% (n=5) have informed their community pharmacist about 
their condition and asked him for advice and information. The 
pharmacist in the community, however is in an ideal position to help 
these epileptics with more information about epilepsy and their 
medication, so as to manage better their condition. 
541 
References 
Ollson, I, Hedstrom A, Epidemiology of absence epilepsy: Concept and 
Incidence. Acta Paediatr. Scand. 1988; 77: 860 - 866 
Sherwin Allan L. in Ethosuximide: Clinical Use in R.Levy, K. Mattson, 
B.Mildrum, J.K.Parry and F.E. Dieifuss Eds. Antiepileptic Drugs: Raven 
Press Ltd. New York 1989 
542 
